Company news: J&J's Janssen

Share this article:
An Arkansas judge levied a $1.2 billion fine on Johnson & Johnson's Janssen after a jury there found the pharma giant guilty of downplaying the risks of its antipsychotic Risperdal. The fine is far and away the largest in a statewide case, though judges and juries in South Carolina, Louisiana and Texas have ordered the firm to pay more than three-quarters of a billion dollars in Risperdal cases combined. J&J's Ortho-McNeil and Janssen units are operating under at federal Corporate Integrity Agreement related to Topamax marketing abuses.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters